Glycosmedia Weekly Diabetes News Update
View this email in your browser

Platinum Sponsors:

Boehringer Ingelheim Lilly

Gold Sponsors:

Novo Nordisk

AstraZeneca

Silver Sponsors:
 

Abbott Diabetes Care

Ericas

Glycosmedia Weekly Diabetes News - 05/29/2020

Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: risks and benefits at the time of COVID ‐19 pandemic

The aim of this manuscript is to comprehensively summarize the current knowledge on the antihyperglycemic properties of HCQ and to critically evaluate the potential risks and benefits related to HCQ use in patients with diabetes, even in light of the current pandemic scenario (Journal of Diabetes)


Comparative effectiveness of dapagliflozin vs DPP ‐4 inhibitors on a composite endpoint of HbA1c , body weight, and blood pressure reduction in the real world

T2D patients initiating the SGLT2i dapagliflozin had a greater probability of attaining a composite endpoint of clinically relevant reductions in HbA1c, body weight and SBP, compared to similar patients initiating a DPP‐4i in the same period and healthcare setting (Diabetes/Metabolism Research and Reviews)


Real-World Glycemic Lowering Effectiveness of Linagliptin Among Adults with Type 2 Diabetes by Age, Renal Function, and Race

These results support the HbA1c-lowering effectiveness of linagliptin across age, race, and renal function categories among a large real-world population of adults with T2DM (Diabetes Therapy)


Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020

Initiating insulin therapy, is recommended at or near the end of each treatment algorithm (JAMA)


CNS Regulation of Glucose Homeostasis: Role of the Leptin-Melanocortin System

The powerful antidiabetic actions of the CNS leptin-melanocortin system are capable of normalizing plasma glucose even in the absence of insulin and involve interactions of multiple neuronal populations and intracellular signaling pathways. Although the links between the CNS leptin-melanocortin system and its chronic effects on peripheral tissue glucose metabolism are still uncertain, they are independent of insulin action, activation of the autonomic nervous system, or the PTA axis (Current Diabetes Reports volume)


Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close

The administration of dipeptidyl peptidase‐4 inhibitors to specific groups of inpatients might be a safe and effective alternative to insulin (Diabetic Medicine)


Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility

The purpose of this review is to summarize the literature evidence that faces the pathophysiological mechanisms underlying bone fragility in T2DM patients (Journal of Diabetes Research)


Prevalence of Microvascular and Macrovascular Disease in the Glycemia Reduction Approaches in Diabetes – A Comparative Effectiveness (GRADE) Study Cohort

In the GRADE cohort with <10 years of T2D and a mean HbA1c of 8.0%, diabetes complications were present in a substantial fraction of participants, more so than might otherwise have been expected (Diabetes Research and Clinical Practice)


Early sepsis markers in patients admitted to intensive care unit with moderate-to-severe diabetic ketoacidosis

At admission, combining procalcitonin and presence of fever may be of value to distinguish ketoacidosis patients with and without proven bacterial infection, admitted in intensive care unit (Annals of Intensive Care)


Share
Tweet
Forward
+1
Share
Please visit the Glycosmedia website for more features and information, including:

Journal Watch
Comment on recently published papers written by the medical editors of Glycosmedia.

Diabetes Updates
Updates written by Professor Steve Bain (Diabetologist) and Dr. Mark Freeman (Diabetologist).

Book and Product Reviews
A selection of book and product reviews written by the contributing editors of Glycosmedia.
The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Glycosmedia complies with the HONcode standard for trustworthy health information: verify here.


Copyright © 2020 Glycosmedia Partnership

Our mailing address is:
Glycosmedia
9 Woodburn Drive
West Cross
Swansea, West Glamorgan SA3 5TZ
United Kingdom

Add us to your address book


unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp